跳至主要内容
临床试验/NCT03382483
NCT03382483已完成不适用

A Prospective, Patient-centric, Observational, Consecutive Enrollment, Non-interventional Study of Patients At Risk for Fracture Non-union Treated With EXOGEN Compared to a National Healthcare Claims Database Control

Bioventus LLC1 个研究点 分布在 1 个国家目标入组 12,387 人开始时间: 2017年10月16日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Bioventus LLC
入组人数
12,387
试验地点
1
主要终点
Adjunctive treatment with low intensity pulsed ultrasound therapy mitigates the risk of fracture non-union in patients at risk

研究概览

简要总结

This study is one of three separate studies of the Bioventus Observational Non-interventional EXOGEN Studies (BONES) program. Eligibility for each study is determined by fractured bone.

详细描述

The prospective arm of this non-interventional, observational study is designed to collect real world evidence from patients at risk of a fracture non-union across the US receiving EXOGEN treatment. Patients will be followed for 9 months post fracture. As a non-interventional study, the treating clinician will continue to provide routine care without research intervention or dictation by a protocol. A medically staffed Direct-to-Patient Contact Center will serve as a central investigational site with scheduled and structured direct-to-patient contacts via phone/email/text/web based surveys to obtain informed consent and collect data directly from the patient. For all prospective patients, primary effectiveness data will be obtained directly from the medical records of the treating physician.

The comparator arm of this study will be a retrospective cohort of patients within a national health insurance claims database. An extract of this database will be taken and eligible controls derived via propensity score analysis.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Other

入排标准

年龄范围
21 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Must be willing to provide voluntary informed consent
  • Male or female age 21-80 on fracture date
  • Must be willing to sign for release of medical insurance claim billing records from the treating clinician, pertaining to the fracture and fracture treatment
  • Fluency in English and/or Spanish
  • Prescriptive initiation of therapy with the EXOGEN Ultrasound Bone Healing System (Model number 71034400) for a specified fracture
  • Bone specific fracture

排除标准

  • Patient report of treatment with an electrical bone growth stimulation device (e.g., pulsed electromagnetic field (PEMF) or capacitive coupling (CC) based devices) for bone fracture in 9-months pre-index period up to baseline phone contact
  • Pregnant on fracture index date
  • Evidence that prescription for EXOGEN has been written to treat a fracture non-union or mal-union (i.e, ICD-10-CM code with seventh character modifier of K, P or S).
  • Evidence that prescription for EXOGEN has been written to treat a pathologic fracture (ICD-10-CM code M
  • or M84.) or neuropathic bone (ICD-10-CM code M14.6)
  • Patient with a concurrent fracture of the other bones of interest
  • Patients who are or anticipate living or receiving fracture treatment outside of the US during the post-index fracture period
  • Patient report of history of primary or metastatic bone cancer
  • Patient report of bone infection or osteomyelitis of index fracture at baseline contact
  • Patient report of prior bone specific fracture in 9-months pre-index period
  • Patient prescribed EXOGEN as part of a Worker Compensation claim

结局指标

主要结局

Adjunctive treatment with low intensity pulsed ultrasound therapy mitigates the risk of fracture non-union in patients at risk

时间窗: 9 month

To compare incidence of fracture non-union in patients utilizing the EXOGEN device with patients receiving standard of care alone

次要结局

未报告次要终点

研究者

发起方
Bioventus LLC
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验